Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Wheeler

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Histopathology|September 24, 2020
Intraductal carcinoma of the prostate is not a diagnostic entityBrett Delahunt, Lars Egevad, Hemamali Samaratunga, et al.
Pathology|July 8, 2019
Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementationJohn R Srigley, Brett Delahunt, Hemamali Samaratunga, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy dataBin S Teh, Gustavo Ayala, Laura Aguilar, et al.
The Oncologist|October 29, 2002
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancerBin S Teh, Estuardo Aguilar-Cordova, Maria T Vlachaki, et al.
Ophthalmic Research|July 8, 2020
New Technologies in Clinical Trials in Corneal Diseases and Limbal Stem Cell Deficiency: Review from the European Vision Institute Special Interest Focus Group MeetingSimona L Schlereth, Deniz Hos, Mario Matthaei, et al.
The New England Journal of Medicine|July 20, 2012
Radical prostatectomy versus observation for localized prostate cancerTimothy J Wilt, Michael K Brawer, Karen M Jones, et al.
Ophthalmic Research|March 31, 2022
Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group MeetingJan-Willem M Beenakker, Niels J Brouwer, Cindy Chau, et al.
Pathology|June 21, 2020
Granular necrosis: a distinctive form of cell death in malignant tumoursHemamali Samaratunga, Brett Delahunt, John R Srigley, et al.
The Journal of Urology|January 10, 2004
Is year of radical prostatectomy a predictor of outcome in prostate cancer?Ilias Cagiannos, Pierre Karakiewicz, Markus Graefen, et al.
The Lancet. Oncology|June 1, 2026
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trialTheodore L DeWeese, Andrea Manzanera, John Sylvester, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Histopathology|September 24, 2020
Intraductal carcinoma of the prostate is not a diagnostic entityBrett Delahunt, Lars Egevad, Hemamali Samaratunga, et al.
Pathology|July 8, 2019
Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementationJohn R Srigley, Brett Delahunt, Hemamali Samaratunga, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy dataBin S Teh, Gustavo Ayala, Laura Aguilar, et al.
The Oncologist|October 29, 2002
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancerBin S Teh, Estuardo Aguilar-Cordova, Maria T Vlachaki, et al.
Ophthalmic Research|July 8, 2020
New Technologies in Clinical Trials in Corneal Diseases and Limbal Stem Cell Deficiency: Review from the European Vision Institute Special Interest Focus Group MeetingSimona L Schlereth, Deniz Hos, Mario Matthaei, et al.
The New England Journal of Medicine|July 20, 2012
Radical prostatectomy versus observation for localized prostate cancerTimothy J Wilt, Michael K Brawer, Karen M Jones, et al.
Ophthalmic Research|March 31, 2022
Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group MeetingJan-Willem M Beenakker, Niels J Brouwer, Cindy Chau, et al.
Pathology|June 21, 2020
Granular necrosis: a distinctive form of cell death in malignant tumoursHemamali Samaratunga, Brett Delahunt, John R Srigley, et al.
The Journal of Urology|January 10, 2004
Is year of radical prostatectomy a predictor of outcome in prostate cancer?Ilias Cagiannos, Pierre Karakiewicz, Markus Graefen, et al.
The Lancet. Oncology|June 1, 2026
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trialTheodore L DeWeese, Andrea Manzanera, John Sylvester, et al.
Pageof 6